<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218397</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00075768</org_study_id>
    <secondary_id>5UM1AI104681</secondary_id>
    <nct_id>NCT03218397</nct_id>
  </id_info>
  <brief_title>Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia</brief_title>
  <acronym>RAPIDS-GN</acronym>
  <official_title>Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the
      following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB):

        1. Standard culture and antimicrobial susceptibility testing (AST); or

        2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the
           Accelerate Pheno™ System (AXDX)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the
      following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB):

        1. Standard culture and antimicrobial susceptibility testing (AST); or

        2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the
           Accelerate Pheno™ System (AXDX)

      Patient specimens with positive blood culture with Gram stain showing GNB identified during
      local laboratory business hours will be enrolled by the Microbiology Laboratory Technologist
      if they do not meet any exclusion criteria. Subject specimens will be randomized 1:1 to
      standard culture and AST or Rapid identification and AST using the FDA approved Accelerate
      Pheno TM System. Both groups will receive standard antimicrobial stewardship (AS). The
      primary service, including the prescribing provider, will be unaware of group assignment at
      the time of randomization, so initial antibiotic choice will not be affected by group
      assignment. Once rapid results become available and/or AS interventions are made, treating
      providers may become aware of group assignment.

      The goal of this study is to determine the impact of rapid bacterial identification and
      phenotypic antimicrobial susceptibility testing (AST) on antimicrobial usage and clinical
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Primary service/provider: The primary service, including the prescribing provider, will be unaware of group assignment at the time of randomization, so initial antibiotic choice will not be affected by group assignment. Once rapid results become available and/or AS interventions are made, treating providers may become aware of group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hours to First Antibiotic Modification</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Mean hours until first modification of antibiotic therapy within 72 hours post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Experienced Mortality Within 30 Days of Randomization</measure>
    <time_frame>Within 30 days of randomization</time_frame>
    <description>Subjects who experienced mortality within 30 days of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in the Hospital</measure>
    <time_frame>Within 30 days of randomization</time_frame>
    <description>Length of stay in the hospital after randomization, up to 30 days, for patients alive at 30 days. Length of stay will be date of discharge minus date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Status Through 72 Hours Post-randomization</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>ICU status through 72 hours post-randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Antibiotic Escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Gram-negative Antibiotic Escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first gram-negative antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Gram-positive Antibiotic Escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first gram-positive antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Antibiotic De-escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Gram-negative Antibiotic De-escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first gram-negative antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Gram-positive Antibiotic De-escalation</measure>
    <time_frame>Within 72 hours of randomization</time_frame>
    <description>Mean hours to first gram-positive antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital-onset Clostridium Difficile Infections</measure>
    <time_frame>Within 30 days of randomization</time_frame>
    <description>Acquisition of hospital-onset Clostridium difficile within 30 days, as defined by the National Healthcare Safety Network (NHSN), normalized to 10,000 patient-days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Hospital-acquired Infections (HAIs) and/or Multidrug Resistant Organisms (MDROs), Normalized to 10,000 Patient-days.</measure>
    <time_frame>Within 30 days of randomization</time_frame>
    <description>Acquisition of new hospital-acquired infections (HAIs) and/or multidrug resistant organisms (MDROs) within 30 days during index hospitalization identified on routine clinical or surveillance samples.
Cultures that will be tracked include the following, from any specimen source, unless otherwise indicated:
Methicillin-resistant Staphylococcus aureus
Vancomycin-resistant Enterococcus
3rd generation cephalosporin non-susceptible Enterobacteriaceae
Carbapenem-resistant Enterobacteriaceae, as defined by the Centers for Disease Control and Prevention (CDC): resistant to imipenem, meropenem, doripenem, or ertapenem OR documentation that the isolate possesses a carbapenemase
Multidrug-resistant Pseudomonas aeruginosa (resistant to aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems)
Carbapenem-resistant Acinetobacter
Candida species (isolated from blood cultures only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Gram-negative Bacteremia</condition>
  <arm_group>
    <arm_group_label>Standard blood culture and AST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid organism identification and AST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerate PhenoTest™ BC Kit</intervention_name>
    <description>Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)</description>
    <arm_group_label>Rapid organism identification and AST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Culture and AST</intervention_name>
    <description>Standard culture and antimicrobial susceptibility testing (AST)</description>
    <arm_group_label>Standard blood culture and AST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive blood culture with Gram stain showing GNB identified during local laboratory
             business hours.

        Exclusion Criteria:

          -  Identification of GNB outside of local laboratory business hours (e.g. whenever
             laboratories are staffed to perform both rapid testing and routine testing)

          -  Positive blood culture for GNB at the same institution within prior 7 days (if known
             at the time of randomization).

          -  Deceased at the time of randomization.

          -  GNB plus gram-positive organism, gram-negative cocci, and/or yeast detected on Gram
             stain

          -  Previous enrollment in this study

          -  No Minnesota research authorization (Rochester site only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ritu Banerjee, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <results_first_submitted>October 17, 2019</results_first_submitted>
  <results_first_submitted_qc>November 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 26, 2019</results_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-negative Bacteremia</keyword>
  <keyword>ICU</keyword>
  <keyword>Critically ill</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Rapid identification</keyword>
  <keyword>Rapid susceptibility</keyword>
  <keyword>Accelerate PhenoTest™ BC Kit</keyword>
  <keyword>Accelerate Pheno™ System (AXDX)</keyword>
  <keyword>Antimicrobial stewardship</keyword>
  <keyword>Antimicrobial use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03218397/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Blood Culture and AST</title>
          <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
        </group>
        <group group_id="P2">
          <title>Rapid Organism Identification and AST</title>
          <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Prior positive blood culture</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Comfort care</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Comfort care and positive blood culture</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Comfort care and mixed culture</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mixed culture</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inaccessible hospital records</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No gram-negative bacilli (GNB)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized during laboratory off hours</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Blood Culture and AST</title>
          <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
        </group>
        <group group_id="B2">
          <title>Rapid Organism Identification and AST</title>
          <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="448"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="18.3"/>
                    <measurement group_id="B2" value="62.2" spread="20.3"/>
                    <measurement group_id="B3" value="64.0" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="393"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hours to First Antibiotic Modification</title>
        <description>Mean hours until first modification of antibiotic therapy within 72 hours post randomization</description>
        <time_frame>72 hours after randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Hours to First Antibiotic Modification</title>
          <description>Mean hours until first modification of antibiotic therapy within 72 hours post randomization</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="24.6"/>
                    <measurement group_id="O2" value="19.0" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first antibiotic modification (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Experienced Mortality Within 30 Days of Randomization</title>
        <description>Subjects who experienced mortality within 30 days of randomization</description>
        <time_frame>Within 30 days of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Experienced Mortality Within 30 Days of Randomization</title>
          <description>Subjects who experienced mortality within 30 days of randomization</description>
          <population>Subjects who completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Dead within 30 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not dead within 30 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.265</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in the Hospital</title>
        <description>Length of stay in the hospital after randomization, up to 30 days, for patients alive at 30 days. Length of stay will be date of discharge minus date of randomization.</description>
        <time_frame>Within 30 days of randomization</time_frame>
        <population>Subjects who were alive at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in the Hospital</title>
          <description>Length of stay in the hospital after randomization, up to 30 days, for patients alive at 30 days. Length of stay will be date of discharge minus date of randomization.</description>
          <population>Subjects who were alive at 30 days.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.7"/>
                    <measurement group_id="O2" value="9.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>T-test for the difference in mean length of stay (days) between treatment arms among subjects alive at 30 days.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Status Through 72 Hours Post-randomization</title>
        <description>ICU status through 72 hours post-randomization</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Status Through 72 Hours Post-randomization</title>
          <description>ICU status through 72 hours post-randomization</description>
          <population>Subjects who completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In ICU &lt; 72 hours after randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In ICU for &gt;= 72 hours after randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Antibiotic Escalation</title>
        <description>Mean hours to first antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Antibiotic Escalation</title>
          <description>Mean hours to first antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="28.8"/>
                    <measurement group_id="O2" value="45.2" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>13.1</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first antibiotic escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Gram-negative Antibiotic Escalation</title>
        <description>Mean hours to first gram-negative antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Gram-negative Antibiotic Escalation</title>
          <description>Mean hours to first gram-negative antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="28.4"/>
                    <measurement group_id="O2" value="47.5" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first gram-negative antibiotic escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Gram-positive Antibiotic Escalation</title>
        <description>Mean hours to first gram-positive antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Gram-positive Antibiotic Escalation</title>
          <description>Mean hours to first gram-positive antibiotic escalation within 72 hours from randomization, where escalation is defined as changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral to intravenous route.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="9.5"/>
                    <measurement group_id="O2" value="69.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first gram-positive antibiotic escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Antibiotic De-escalation</title>
        <description>Mean hours to first antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Antibiotic De-escalation</title>
          <description>Mean hours to first antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="26.2"/>
                    <measurement group_id="O2" value="39.6" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first antibiotic de-escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Gram-negative Antibiotic De-escalation</title>
        <description>Mean hours to first gram-negative antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Gram-negative Antibiotic De-escalation</title>
          <description>Mean hours to first gram-negative antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="23.5"/>
                    <measurement group_id="O2" value="49.3" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first gram-negative antibiotic de-escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Gram-positive Antibiotic De-escalation</title>
        <description>Mean hours to first gram-positive antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
        <time_frame>Within 72 hours of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Gram-positive Antibiotic De-escalation</title>
          <description>Mean hours to first gram-positive antibiotic de-escalation within 72 hours from randomization, where de-escalation is defined as changing to a narrower spectrum antibiotic, cessation of one or more antibiotics, or changing from an intravenous to oral route of appropriate drug.</description>
          <population>Subjects who completed the study.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="22.6"/>
                    <measurement group_id="O2" value="62.2" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in means</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Difference in mean hours to first gram-positive antibiotic de-escalation (Standard Blood Culture and AST minus Rapid Organism Identification and AST)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital-onset Clostridium Difficile Infections</title>
        <description>Acquisition of hospital-onset Clostridium difficile within 30 days, as defined by the National Healthcare Safety Network (NHSN), normalized to 10,000 patient-days.</description>
        <time_frame>Within 30 days of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital-onset Clostridium Difficile Infections</title>
          <description>Acquisition of hospital-onset Clostridium difficile within 30 days, as defined by the National Healthcare Safety Network (NHSN), normalized to 10,000 patient-days.</description>
          <population>Subjects who completed the study.</population>
          <units>Infections per 10,000 patient-days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="11.2" upper_limit="64.4"/>
                    <measurement group_id="O2" value="27.5" lower_limit="12.4" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Hospital-acquired Infections (HAIs) and/or Multidrug Resistant Organisms (MDROs), Normalized to 10,000 Patient-days.</title>
        <description>Acquisition of new hospital-acquired infections (HAIs) and/or multidrug resistant organisms (MDROs) within 30 days during index hospitalization identified on routine clinical or surveillance samples.
Cultures that will be tracked include the following, from any specimen source, unless otherwise indicated:
Methicillin-resistant Staphylococcus aureus
Vancomycin-resistant Enterococcus
3rd generation cephalosporin non-susceptible Enterobacteriaceae
Carbapenem-resistant Enterobacteriaceae, as defined by the Centers for Disease Control and Prevention (CDC): resistant to imipenem, meropenem, doripenem, or ertapenem OR documentation that the isolate possesses a carbapenemase
Multidrug-resistant Pseudomonas aeruginosa (resistant to aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems)
Carbapenem-resistant Acinetobacter
Candida species (isolated from blood cultures only)</description>
        <time_frame>Within 30 days of randomization</time_frame>
        <population>Subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Blood Culture and AST</title>
            <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
          </group>
          <group group_id="O2">
            <title>Rapid Organism Identification and AST</title>
            <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Hospital-acquired Infections (HAIs) and/or Multidrug Resistant Organisms (MDROs), Normalized to 10,000 Patient-days.</title>
          <description>Acquisition of new hospital-acquired infections (HAIs) and/or multidrug resistant organisms (MDROs) within 30 days during index hospitalization identified on routine clinical or surveillance samples.
Cultures that will be tracked include the following, from any specimen source, unless otherwise indicated:
Methicillin-resistant Staphylococcus aureus
Vancomycin-resistant Enterococcus
3rd generation cephalosporin non-susceptible Enterobacteriaceae
Carbapenem-resistant Enterobacteriaceae, as defined by the Centers for Disease Control and Prevention (CDC): resistant to imipenem, meropenem, doripenem, or ertapenem OR documentation that the isolate possesses a carbapenemase
Multidrug-resistant Pseudomonas aeruginosa (resistant to aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems)
Carbapenem-resistant Acinetobacter
Candida species (isolated from blood cultures only)</description>
          <population>Subjects who completed the study.</population>
          <units>Infections per 10,000 patient-days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.3" lower_limit="82.0" upper_limit="185.6"/>
                    <measurement group_id="O2" value="105.5" lower_limit="70.1" upper_limit="158.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days from randomization</time_frame>
      <desc>With the exception of mortality, adverse events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Blood Culture and AST</title>
          <description>Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.</description>
        </group>
        <group group_id="E2">
          <title>Rapid Organism Identification and AST</title>
          <description>Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vance Fowler, MD, MHS</name_or_title>
      <organization>Duke University</organization>
      <phone>919-613-5678</phone>
      <email>vance.fowler@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

